Needham downgrades Hologic ahead of COVID-19 testing decline

Needham analyst Mike Matson downgraded Hologic to Hold from Buy without a price target. The company is seeing a “massive benefit” from COVID-19 testing, but testing sales will begin to decline in 2021, Matson tells investors in a research note. While COVID will bring “sustainable benefits,” investors are mostly ignoring Hologic’s COVID-19 testing “windfall,” and vaccine developments will further weigh on sentiment, says the analyst.

Matson thinks Hologic shares should be valued on the company’s post-COVID-19 earnings power. His “best guess at this point” is that the company’s post-COVID-19 earnings power per share is $3.68 in fiscal 2022. On this valuation Matson downgrades the shares to Hold.

Related posts

Carl Icahn Increases His Stake In Take-Two Interactive To 10.68%

ValueWalk

iPad Mini Display Outperformed By Kindle Fire HD & Nexus 7

ValueWalk

Foxconn Might Open Manufacturing Plants In The U.S. [REPORT]

ValueWalk

Peter Cundill Protégé Tim McElvaine on Investing in Japan [VIDEO]

ValueWalk

Set Bing Home Page Image As Lock Screen In Windows 8

ValueWalk

Morning Market News: JCP, APO, MCHP, ZIP, ENR, LGF, EA, ATVI, COV, LNT

ValueWalk